Prevention of Alzheimer's Disease in Women: Risks and Benefits of Hormone Therapy -Continuation of: "The Kronos Early Estrogen Prevention Study (KEEPS)" Mayo Clinic IRB#2241-04-00
Phase of Trial: Phase IV
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Florbetapir F 18 (Primary) ; Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 17 Apr 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2019 to 1 Jun 2019.
- 05 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2018 to 1 Mar 2019.
- 01 Nov 2018 New trial record